Navigation Links
50,000 Potassium Iodide Pills Donated to Japan
Date:3/15/2011

MOORESVILLE, N.C., March 15, 2011 /PRNewswire/ -- Approximately 50,000 potassium iodide tablets have been donated by Nukepills.com to Tokushukai Hospital in Tokyo, Japan for immediate distribution to those affected by Japan's nuclear reactor crisis. This effort was facilitated by Dr. Alisa Suzuki Han, Radiologist at Brigham and Women's Hospital, a teaching facility of Harvard Medical School, in Boston, MA. The radiation-blocking drug, currently en route to Japan, will be distributed by the Tokushukai Medical Aid Team. "We are very pleased that these tablets will be given to people directly affected by the nuclear crisis," stated Troy Jones, President of Nukepills.com. "The efforts of Dr. Han and the Tokushukai Medical Aid Team are a wonderful example of professionals coming together to ensure the health and livelihood of those most in need."

Stockpiling of potassium iodide is recommended by health officials worldwide to prevent thyroid cancer of those exposed to radioactive iodine in the event of a nuclear reactor accident or detonation of a nuclear bomb. FDA approved in 1982, potassium iodide is available without a prescription. More information about FDA approved potassium iodide can be found online at http://www.nukepills.com.

Nukepills.com, celebrating its 12th year in business, is an Internet-based supplier of radiation emergency preparedness products that protect against dirty bomb radiation, nuclear reactor accidents and nuclear weapon fallout, and are used for radiation therapy/decontamination in hospitals. The company was founded in 1999 as a means of supplying FDA approved Iosat(TM) Potassium Iodide directly to the general public and now has international sales programs throughout Canada, Europe, Asia and the Middle East. In early 2009, Nukepills.com sold 5.4 million doses of FDA approved ThyroShield(TM) Liquid Potassium Iodide to Kuwait's Ministry of Health and expects Government Emergency Preparedness grants and civilian orders to continue to drive sales of all of its products well into 2011.

Logo: http://www.ereleases.com/pic/Nukepills-logo.jpg Contact: Troy Jones, President, Nukepills.comPh: 866-283-3986info@nukepills.com 631 Brawley School Rd STE 407Mooresville, NC 28117http://www.nukepills.com Twitter: http://twitter.com/nukepills This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Nukepills.com
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Will Rogers Institute Awards Top Doctor $50,000 for Outstanding Contributions to Lung Research
2. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
3. $250,000 Awarded to Smartfield, Inc. of Lubbock, TX by the Texas Emerging Technology Fund
4. BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts
5. Intralink-Spine Inc. Awarded $750,000 Small Business Innovation Research Phase II Grant
6. March of Dimes Awards $250,000 Prize to Scientist Who Discovered How to Reprogram Human Cells
7. Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
8. Collexis BiomedExperts Fast Approaching 150,000 Registered Users
9. ZINO Society Spurring Investments, 12 Life Sciences Companies to Vie for $50,000 ZINO Life Fund
10. Huntington Area Development Council Attracts Technology-Based Startup Companies With $150,000 Grant From Verizon West Virginia
11. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):